FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104000886> ?p ?o ?g. }

• W2104000886 endingPage "468" @default.
• W2104000886 startingPage "461" @default.
• W2104000886 abstract "Intravenous tissue plasminogen activator (tPA) given within 4.5 h of symptom onset is accepted as the standard treatment of ischemic stroke. Persistent occlusion of cerebral arteries despite intravenous thrombolysis and unremitting neurologic deficits lead us to consider additional intra-arterial approaches. The aim of this study was to elucidate the potential of fluid-attenuated inversion recovery (FLAIR) MRI performed during or immediately after intravenous thrombolysis for predicting clinical outcomes of subsequent intra-arterial thrombolysis.With a prospective stroke registry database of patients hospitalized in our institution from January 2004 to February 2010, we identified ischemic stroke patients with the following conditions: (1) presentation within 2.5 h of onset, (2) treated with intravenous tPA based on brain CT, (3) persistent occlusion on subsequent MRI/MR angiography, including a FLAIR sequence, and (4) eventually treated with intra-arterial thrombolysis. Demographic, clinical and laboratory findings including initial National Institutes of Health Stroke Scale (NIHSS), follow-up NIHSS at the 7th day or discharge, modified Rankin scale (mRS) score at 3 months, and symptomatic hemorrhagic transformation were captured. FLAIR images were reviewed by 2 investigators blinded to clinical information independently and dichotomized into the absence and presence of FLAIR change within the diffusion-restriction lesions.Of the 57 patients who met these conditions, FLAIR-hyperintense lesions (FHL) were observed in 32 (56.1%). The FHL-negative group was 69.1 ± 12.1 years old on average and the FHL-positive group 67.3 ± 11.0 years old. In both groups, hypertension was the most common vascular risk factor, cardioembolic stroke was the most common subtype, and distal middle cerebral artery was the most common site of occlusion. The incidence of symptomatic hemorrhagic transformation was 4.0% in the FHL-negative group and 9.4% in the FHL-positive group (p = 0.62). NIHSS scores of 0-1 on the 7th day of hospitalization or at discharge were observed in 36% of the FHL-negative group and in 9.4% of the FHL-positive group; mRS scores of 0-1 at 3 months was 32% in the FHL-negative group and 21% in the FHL-positive group. An ordinal logistic regression analysis showed that the presence of FHL was associated with higher 7-day NIHSS scores (adjusted for relevant covariates) but not with higher 3-month mRS scores.This study suggests that the FHL might be used as imaging biomarker to predict outcomes for additional intra-arterial thrombolysis in patients treated with intravenous tPA." @default.
• W2104000886 created "2016-06-24" @default.
• W2104000886 creator A5000627464 @default.
• W2104000886 creator A5009851092 @default.
• W2104000886 creator A5017587887 @default.
• W2104000886 creator A5022869761 @default.
• W2104000886 creator A5026991273 @default.
• W2104000886 creator A5028720354 @default.
• W2104000886 creator A5035547791 @default.
• W2104000886 creator A5038702450 @default.
• W2104000886 creator A5041945349 @default.
• W2104000886 creator A5052764732 @default.
• W2104000886 creator A5057126432 @default.
• W2104000886 creator A5068019940 @default.
• W2104000886 creator A5071917675 @default.
• W2104000886 date "2013-01-01" @default.
• W2104000886 modified "2023-09-27" @default.
• W2104000886 title "Validation of FLAIR Hyperintense Lesions as Imaging Biomarkers to Predict the Outcome of Acute Stroke after Intra-Arterial Thrombolysis following Intravenous Tissue Plasminogen Activator" @default.
• W2104000886 cites W132472807 @default.
• W2104000886 cites W1980572444 @default.
• W2104000886 cites W1984414276 @default.
• W2104000886 cites W2007262117 @default.
• W2104000886 cites W2010079726 @default.
• W2104000886 cites W2011815816 @default.
• W2104000886 cites W2016234644 @default.
• W2104000886 cites W2022848880 @default.
• W2104000886 cites W2036653122 @default.
• W2104000886 cites W2055477368 @default.
• W2104000886 cites W2062960487 @default.
• W2104000886 cites W2069084981 @default.
• W2104000886 cites W2103291754 @default.
• W2104000886 cites W2104657667 @default.
• W2104000886 cites W2104736983 @default.
• W2104000886 cites W2106324086 @default.
• W2104000886 cites W2119116797 @default.
• W2104000886 cites W2129847994 @default.
• W2104000886 cites W2130234373 @default.
• W2104000886 cites W2134605661 @default.
• W2104000886 cites W2148067100 @default.
• W2104000886 cites W2150556376 @default.
• W2104000886 cites W2155681330 @default.
• W2104000886 cites W2158551075 @default.
• W2104000886 cites W2163389355 @default.
• W2104000886 cites W2170486603 @default.
• W2104000886 cites W2171240693 @default.
• W2104000886 cites W2594075545 @default.
• W2104000886 cites W4250104750 @default.
• W2104000886 doi "https://doi.org/10.1159/000350201" @default.
• W2104000886 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23735898" @default.
• W2104000886 hasPublicationYear "2013" @default.
• W2104000886 type Work @default.
• W2104000886 sameAs 2104000886 @default.
• W2104000886 citedByCount "16" @default.
• W2104000886 countsByYear W21040008862014 @default.
• W2104000886 countsByYear W21040008862015 @default.
• W2104000886 countsByYear W21040008862016 @default.
• W2104000886 countsByYear W21040008862017 @default.
• W2104000886 countsByYear W21040008862018 @default.
• W2104000886 countsByYear W21040008862019 @default.
• W2104000886 countsByYear W21040008862020 @default.
• W2104000886 countsByYear W21040008862021 @default.
• W2104000886 countsByYear W21040008862022 @default.
• W2104000886 countsByYear W21040008862023 @default.
• W2104000886 crossrefType "journal-article" @default.
• W2104000886 hasAuthorship W2104000886A5000627464 @default.
• W2104000886 hasAuthorship W2104000886A5009851092 @default.
• W2104000886 hasAuthorship W2104000886A5017587887 @default.
• W2104000886 hasAuthorship W2104000886A5022869761 @default.
• W2104000886 hasAuthorship W2104000886A5026991273 @default.
• W2104000886 hasAuthorship W2104000886A5028720354 @default.
• W2104000886 hasAuthorship W2104000886A5035547791 @default.
• W2104000886 hasAuthorship W2104000886A5038702450 @default.
• W2104000886 hasAuthorship W2104000886A5041945349 @default.
• W2104000886 hasAuthorship W2104000886A5052764732 @default.
• W2104000886 hasAuthorship W2104000886A5057126432 @default.
• W2104000886 hasAuthorship W2104000886A5068019940 @default.
• W2104000886 hasAuthorship W2104000886A5071917675 @default.
• W2104000886 hasConcept C101070640 @default.
• W2104000886 hasConcept C126322002 @default.
• W2104000886 hasConcept C126838900 @default.
• W2104000886 hasConcept C127413603 @default.
• W2104000886 hasConcept C143409427 @default.
• W2104000886 hasConcept C146638467 @default.
• W2104000886 hasConcept C164705383 @default.
• W2104000886 hasConcept C2776191500 @default.
• W2104000886 hasConcept C2776572282 @default.
• W2104000886 hasConcept C2779581417 @default.
• W2104000886 hasConcept C2780645631 @default.
• W2104000886 hasConcept C2780931571 @default.
• W2104000886 hasConcept C3020199598 @default.
• W2104000886 hasConcept C500558357 @default.
• W2104000886 hasConcept C541997718 @default.
• W2104000886 hasConcept C71924100 @default.
• W2104000886 hasConcept C78519656 @default.
• W2104000886 hasConceptScore W2104000886C101070640 @default.
• W2104000886 hasConceptScore W2104000886C126322002 @default.
• W2104000886 hasConceptScore W2104000886C126838900 @default.
• W2104000886 hasConceptScore W2104000886C127413603 @default.

• next